The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The Ras-Raf-MAPK pathway has been implicated in lung carcinogenesis and, potentially, the maintenance of the malignant phenotype in these tumors. Mutations in ras and B-raf genes have been described in lung cancer, representing one of the few examples of tandem mutations in a signaling cascade. As a result, numerous approaches to inhibiting this pathway in lung cancer have been explored in the past decade. The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed.

Original languageEnglish (US)
Pages (from-to)221-223
Number of pages3
JournalClinical lung cancer
Issue number3
StatePublished - Nov 2005


  • MAP kinase
  • Mutations
  • Raf
  • Ras
  • Signaling pathways

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy'. Together they form a unique fingerprint.

Cite this